115 related articles for article (PubMed ID: 37001185)
1. Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment.
Lee O; Wang M; Hosseini O; Bosland MC; Muzzio M; Helenowski I; Khan SA
Biomed Pharmacother; 2023 Jun; 162():114607. PubMed ID: 37001185
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
[TBL] [Abstract][Full Text] [Related]
3. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
4. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
5. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.
Zhang C; Zhong Q; Zhang Q; Zheng S; Miele L; Wang G
Breast Cancer Res Treat; 2015 Jul; 152(2):283-91. PubMed ID: 26071758
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
7. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
9. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
[TBL] [Abstract][Full Text] [Related]
10. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
[TBL] [Abstract][Full Text] [Related]
11. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Goetz MP; Suman VJ; Reid JM; Northfelt DW; Mahr MA; Ralya AT; Kuffel M; Buhrow SA; Safgren SL; McGovern RM; Black J; Dockter T; Haddad T; Erlichman C; Adjei AA; Visscher D; Chalmers ZR; Frampton G; Kipp BR; Liu MC; Hawse JR; Doroshow JH; Collins JM; Streicher H; Ames MM; Ingle JN
J Clin Oncol; 2017 Oct; 35(30):3391-3400. PubMed ID: 28854070
[TBL] [Abstract][Full Text] [Related]
13. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells.
Ribeiro MP; Silva FS; Paixão J; Santos AE; Custódio JB
Eur J Pharmacol; 2013 Sep; 715(1-3):354-62. PubMed ID: 23712006
[TBL] [Abstract][Full Text] [Related]
14. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
15. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
[TBL] [Abstract][Full Text] [Related]
16. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
17. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
18. Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
Chan JC; Ong PS; Lim P; Teng PX; Chan EC
Cancer Chemother Pharmacol; 2017 Jan; 79(1):117-130. PubMed ID: 27942916
[TBL] [Abstract][Full Text] [Related]
19. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
[TBL] [Abstract][Full Text] [Related]
20. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.
Lee O; Bazzi LA; Xu Y; Pearson E; Wang M; Hosseini O; Akasha AM; Choi JN; Karlan S; Pilewskie M; Kocherginsky M; Benante K; Helland T; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Khan SA
Biomed Pharmacother; 2024 Feb; 171():116105. PubMed ID: 38171245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
